TP53 and endometrial cancer: Immunohistochemistry (IHC), which has been applied for subclassification of endometrial cancer, as a surrogate marker for hormone sensitivity, was performed along with analysis of genetic and/or epigenetic alterations in TP53, PTEN, and ARID1A (which are frequent mutations in endometrial cancer) and DNA mismatch repair genes29,30.